Natco Pharma Limited
Regd. Off.: 'NATCO HOUSE', Road No.- 2, Banjara Hills, Hyderabad, Telangana, India- 500 034
Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

28th September, 2026

Corporate Relationship Department
M/s. BSE Limited
Mumbai 400001

Scrip Code: 524816

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Bandra (E), Mumbai 400051

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Ref: Earlier intimation dated 25th August, 2026 regarding the investment in eGenesis, Inc.

With reference to the above cited subject, NATCO Pharma Limited ("NATCO") has decided to increase its investment in eGenesis, Inc. from the previously disclosed amount of US$14.00 million to US$16.70 million through its wholly owned subsidiaries. In addition, there has been a change in the subsidiaries participating in the investment. The updated details of the investment and the subsidiaries involved are set out in the Annexure.

Please find enclosed herewith the Disclosure and Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the investment in eGenesis, Inc.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

VENKAT RAMESH CHEKURI
Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.09.28 14:54:05 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: As above

Press Release

NATCO

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Update to disclosure dated August 25, 2026 under SEBI (LODR) Regulations, 2015

This is in furtherance of the disclosure made by NATCO Pharma Limited on August 25, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”).

NATCO Pharma Limited ("NATCO") has decided to increase its investment in eGenesis, Inc. from the previously disclosed amount of **US$14.00 million** to **US$16.70 million** through its wholly owned subsidiaries. In addition, there has been a change in the subsidiaries participating in the investment. The updated details of the investment and the subsidiaries involved are set out in the accompanying disclosure submitted under the LODR Regulations.

Earlier, in 2024, NATCO had invested **US$8.00 million** in eGenesis through NATCO Pharma (Canada) Inc. Upon completion of the proposed investment, NATCO's total investment in eGenesis will increase to **US$24.70 million**.

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure and heart transplant.

In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway. It was followed by porcine kidney transplants in additional two patients. The outcomes have been exceptionally positive.

About NATCO Pharma Limited

NATCO Pharma Limited is a vertically integrated pharmaceutical company headquartered in Hyderabad, India. With a strong focus on research and development, NATCO Pharma is dedicated to delivering high-quality and affordable medicines to patients worldwide.

About eGenesis, Inc.

eGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.

For further information or queries please contact:

Rajeev Menon – Manager, Investor Relations
Email: r.menon@natcopharma.co.in
Tel: 040-23547532 / Ext – 323

Follow us on:

X (formerly Twitter): https://twitter.com/pharma_natco

LinkedIn: https://www.linkedin.com/company/natcopharma

Natco Pharma Limited
Regd. Off.: 'NATCO HOUSE', Road No.- 2, Banjara Hills, Hyderabad, Telangana, India- 500 034
Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Annexure

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201a5

The below disclosure is being made in further to our disclosure dated August 25, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Investment of US$ 16.70 million in eGenesis, Inc., comprising US$ 13.70 million by NATCO Pharma (Canada) Inc. and US$ 3 million by NATCO Pharma USA LLC through convertible promissory notes

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	1) **Name of the target entity** eGenesis, Inc. 2) **Details in brief such as size, turnover etc.** It is an R&D company engaged in using its multiplex gene editing and genome engineering platform to research and develop porcine solid organ donors for use in human transplantation for patients with serious diseases causing organ failure.
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
C	Industry to which the entity being acquired belongs	Biotechnology
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Investing in new-age therapeutic programmes addressing critical unmet medical needs
E	Brief details of any governmental or regulatory approvals required for the acquisition	-
F	Indicative time period for completion of the acquisition;	October 31, 2026
G	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration for subscribing to convertible promissory notes
H	Cost of acquisition or the price at which the shares are acquired	US$ 13.70 million by NATCO Pharma (Canada) Inc. and US$ 3 million by NATCO Pharma USA LLC

Sl. No.	Particulars	Details of Investment
I	Percentage of shareholding / control acquired and / or number of shares acquired	NATCO Pharma (Canada) Inc. is purchasing a Convertible Promissory Note with a principal amount of US$ 13.70 million with an interest rate of 8% compounded annually and NATCO Pharma USA LLC is purchasing a Convertible Promissory Note with a principal amount of US$ 3 million with an interest rate of 8% compounded annually. At the time of completion of this acquisition, no additional shares are being acquired.
J	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	1. **Brief background:** eGenesis, Inc. is a clinical stage company engaged in using its multiplex gene editing and genome engineering platform to address numerous mechanisms of human rejection of non-human organs. The company is currently in clinical trials for porcine kidney transplantation in humans and porcine liver perfusion with a goal of addressing the fundamental limitation of human donor availability for patients with serious diseases resulting in acute and chronic organ failure. 2. **Line of business:** Biotechnology 3. **Date of incorporation:** October 1, 2015 4. **Turnover of last 3 years ending December 31 (in US$ million):** The company is a clinical stage company and pre-revenue 5. **Country in which the acquired entity will have presence:** United States of America